Anne Elizabeth Ioannides
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anne Elizabeth Ioannides has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer Kathleen Quint
Imperial College London
9 shared publications Constantinos Kallis
School of Public Health, Imperial College London, London, UK
3 shared publications- Emily L. Graul
School of Public Health, Imperial College London, London, UK
2 shared publications - Hannah Whittaker
School of Public Health, Imperial College London, London, UK
2 shared publications - Ann Dorothy Morgan
National Heart and Lung Institute, Imperial College London, London, UK
1 shared publication - Clementine Nordon
Respiratory Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
COPD exacerbations and Major Adverse Cardiovascular Events (MACE) after first MACE
Whether major adverse cardiovascular events (MACE) are associated with subsequent COPD exacerbations is unknown. In a generalisable COPD cohort, we determined whether (1) MACE was associated with subsequent exacerbations (by MACE-subtype, exacerbation severity, and timeframe), and (2) exacerbation-plus-MACE was associated with second non-fatal MACE. We conducted a cohort study using the Clinical Practice Research Datalink (CPRD) Aurum primary care database, linked with inpatient secondary care (Hospital Episode Statistics) and mortality (Office of National Statistics), between 01/01/2010 and 27/03/2021. For aim (1), exposure was MACE (first hospitalised acute coronary syndrome, arrhythmia, ischaemic stroke, or heart failure) versus no MACE, and outcome was exacerbations. For aim (2), exposure was exacerbation within the year preceding first MACE (MACE-plus-exacerbation), versus MACE alone, and outcome second non-fatal MACE. As an exploratory analysis, we determined whether inhaled corticosteroids (ICS) were associated with subsequent MACE in people with different cardiovascular histories. We implemented Cox proportional hazard regressions. Amongst 291 161 individuals with COPD (21 108[7.2%] with MACE), MACE and MACE-subtypes were associated with subsequent exacerbations (aHR[95%CI]=1.32[1.29–1.35], p<0.00001), driven primarily by severe exacerbations (moderate: aHR[95%CI]=1.06[1.02–1.10], p=0.0009; severe: aHR[95%CI]=1.86[1.78–1.94], p<0.00001). Exacerbation risk was reduced in days 1–14 post-MACE (aHR[95%CI]=0.78[0.68–0.89], p<0.00001), likely due to healthcare contact, followed by a sharp increase between days 15–30 (aHR[95%CI]=2.12[1.92–2.34], p<0.00001), and a reduction to average risk over one year. Exacerbation-plus-MACE was not associated with second non-fatal MACE (aHR[95%CI]=1.07[0.99–1.14]), regardless of MACE-subtype and exacerbation severity. ICS, compared with long-acting bronchodilators, was not associated with subsequent MACE, regardless of cardiovascular history. MACE was associated with subsequent exacerbations, particularly severe exacerbations. Risk is highest 15–30 days post-MACE. Exacerbation-plus-MACE was not associated with second non-fatal MACE compared with MACE alone.
- 13 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessCOPD exacerbations and Major Adverse Cardiovascular Events (MACE) after first MACE
Whether major adverse cardiovascular events (MACE) are associated with subsequent COPD exacerbations is unknown. In a generalisable COPD cohort, we determined whether (1) MACE was associated with subsequent exacerbations (by MACE-subtype, exacerbation severity, and timeframe), and (2) exacerbation-plus-MACE was associated with second non-fatal MACE. We conducted a cohort study using the Clinical Practice Research Datalink (CPRD) Aurum primary care database, linked with inpatient secondary care (Hospital Episode Statistics) and mortality (Office of National Statistics), between 01/01/2010 and 27/03/2021. For aim (1), exposure was MACE (first hospitalised acute coronary syndrome, arrhythmia, ischaemic stroke, or heart failure) versus no MACE, and outcome was exacerbations. For aim (2), exposure was exacerbation within the year preceding first MACE (MACE-plus-exacerbation), versus MACE alone, and outcome second non-fatal MACE. As an exploratory analysis, we determined whether inhaled corticosteroids (ICS) were associated with subsequent MACE in people with different cardiovascular histories. We implemented Cox proportional hazard regressions. Amongst 291 161 individuals with COPD (21 108[7.2%] with MACE), MACE and MACE-subtypes were associated with subsequent exacerbations (aHR[95%CI]=1.32[1.29–1.35], p<0.00001), driven primarily by severe exacerbations (moderate: aHR[95%CI]=1.06[1.02–1.10], p=0.0009; severe: aHR[95%CI]=1.86[1.78–1.94], p<0.00001). Exacerbation risk was reduced in days 1–14 post-MACE (aHR[95%CI]=0.78[0.68–0.89], p<0.00001), likely due to healthcare contact, followed by a sharp increase between days 15–30 (aHR[95%CI]=2.12[1.92–2.34], p<0.00001), and a reduction to average risk over one year. Exacerbation-plus-MACE was not associated with second non-fatal MACE (aHR[95%CI]=1.07[0.99–1.14]), regardless of MACE-subtype and exacerbation severity. ICS, compared with long-acting bronchodilators, was not associated with subsequent MACE, regardless of cardiovascular history. MACE was associated with subsequent exacerbations, particularly severe exacerbations. Risk is highest 15–30 days post-MACE. Exacerbation-plus-MACE was not associated with second non-fatal MACE compared with MACE alone.
- Open Access
- 5 March 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (1) , 2502555
Developing and Validating the CE-MACE Model to Predict One-Year Major Adverse Cardiovascular Events Post COPD Exacerbation Using Routine Healthcare Data
Background: Patients with chronic obstructive pulmonary disease (COPD) are at an elevated risk of cardiovascular events, particularly following acute exacerbations. Existing prediction models underestimate their risk. We developed and validated the CE-MACE model to predict one-year major adverse cardiovascular event (MACE) risk following a COPD exacerbation. Methods: Using electronic health records from the UK Clinical Practice Research Datalink (CPRD) Aurum database, we included patients aged ≥40-years-old with moderate or severe COPD exacerbations. The outcome was fatal or non-fatal MACE (acute coronary syndrome, arrhythmia, heart failure, or ischemic stroke). Cause-specific hazard models were used to estimate the coefficient of predictors. Model performance was assessed by Nagelkerke's R 2 , Harrell's C statistic, calibration-in-the-large, calibration slope, and decision curve analysis. Internal-external cross validation was used to evaluate model performance across nine geographic regions. A risk score was derived from the original coefficients. Results: A total of 338 981 patients were included. The overall one-year cumulative incidence rate of MACE following COPD exacerbation was 5.04% (4.96–5.12%). Six predictors were retained: age, exacerbation severity, MACE history, mMRC dyspnoea scale, hypertension, and diabetes. In internal-external cross validation, the pooled estimation for Nagelkerke's R 2 was 3.120% (2.945–3.295%), Harrell's C statistic was 0.752 (0.746–0.759). Calibration-in-the-large was −0.006 (−0.008– −0.004) and calibration slope equal to 0.999 (0.977–1.020). The model suggested clinical utility with higher net benefit than default strategies across the risk thresholds range from 2% to 18%. Model-driven risk stratification demonstrated significantly different cumulative incidence rates among these risk categories. Sensitivity analysis revealed that the CE-MACE model is generalisable to those patients with any history of COPD exacerbation. Conclusion: The CE-MACE highlights the burden of cardiovascular multimorbidity in patients with COPD. The model could help precisely identify those at high risk in clinical practice and promote integrated multidisciplinary healthcare for these patients.
- 5 March 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (1) , 2502555
Open AccessDeveloping and Validating the CE-MACE Model to Predict One-Year Major Adverse Cardiovascular Events Post COPD Exacerbation Using Routine Healthcare Data
Background: Patients with chronic obstructive pulmonary disease (COPD) are at an elevated risk of cardiovascular events, particularly following acute exacerbations. Existing prediction models underestimate their risk. We developed and validated the CE-MACE model to predict one-year major adverse cardiovascular event (MACE) risk following a COPD exacerbation. Methods: Using electronic health records from the UK Clinical Practice Research Datalink (CPRD) Aurum database, we included patients aged ≥40-years-old with moderate or severe COPD exacerbations. The outcome was fatal or non-fatal MACE (acute coronary syndrome, arrhythmia, heart failure, or ischemic stroke). Cause-specific hazard models were used to estimate the coefficient of predictors. Model performance was assessed by Nagelkerke's R 2 , Harrell's C statistic, calibration-in-the-large, calibration slope, and decision curve analysis. Internal-external cross validation was used to evaluate model performance across nine geographic regions. A risk score was derived from the original coefficients. Results: A total of 338 981 patients were included. The overall one-year cumulative incidence rate of MACE following COPD exacerbation was 5.04% (4.96–5.12%). Six predictors were retained: age, exacerbation severity, MACE history, mMRC dyspnoea scale, hypertension, and diabetes. In internal-external cross validation, the pooled estimation for Nagelkerke's R 2 was 3.120% (2.945–3.295%), Harrell's C statistic was 0.752 (0.746–0.759). Calibration-in-the-large was −0.006 (−0.008– −0.004) and calibration slope equal to 0.999 (0.977–1.020). The model suggested clinical utility with higher net benefit than default strategies across the risk thresholds range from 2% to 18%. Model-driven risk stratification demonstrated significantly different cumulative incidence rates among these risk categories. Sensitivity analysis revealed that the CE-MACE model is generalisable to those patients with any history of COPD exacerbation. Conclusion: The CE-MACE highlights the burden of cardiovascular multimorbidity in patients with COPD. The model could help precisely identify those at high risk in clinical practice and promote integrated multidisciplinary healthcare for these patients.
- Open Access
- 4 March 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
The role of COPD and inhaled corticosteroids in major adverse cardiovascular events in cardiovascular-kidney-metabolic populations
Background: Cardiovascular-kidney-metabolic (CKM) disease and chronic obstructive pulmonary disease (COPD) are associated with major adverse cardiovascular events (MACE). Whether COPD further increases MACE risk within CKM populations, and whether this potential risk is modifiable through inhaled corticosteroids (ICS), is unknown. Within CKM populations, we investigated the relationship between (1) COPD and subsequent MACE, and (2) amongst concurrent CKM-COPD populations, we investigated the relationship between ICS and subsequent MACE. Methods: We used Clinical Practice Research Datalink (CPRD) Aurum, Hospital Episode Statistics and Office of National Statistics data, between January 1st, 2010, and March 29th, 2021. We created five discrete cohorts: chronic kidney disease (CKD), type-II diabetes mellitus (T2DM), obesity, MACE history, and older adults (aged ≥ 65 years old [“Age65 + ”]). CKD, T2DM, obesity, and Age65 + cohorts were MACE-naïve at the time of inclusion. Aim (1) exposures were (a) COPD, (b) incident COPD, and (c) being at risk of COPD without diagnosis (defined as age ≥ 40 years old, smoking history, no evidence of asthma, and frequent respiratory infections requiring antibiotics). Aim (2) exposure was ICS prescription (control group: long-acting bronchodilators). The outcome was MACE (acute coronary syndrome, arrhythmia, heart failure, ischaemic stroke, or cardiovascular-specific mortality). We implemented Cox proportional hazards models. Results: COPD was associated with MACE amongst all cohorts, but was comparatively weak in the MACE history cohort (cohort total; adjusted hazard ratio [95% confidence interval]): CKD ( N = 573,626; 1.29 [1.26, 1.32]), T2DM ( N = 649,506; 1.30 [1.26, 1.35], obesity ( N = 225,273; 1.41 [1.34, 1.48]), MACE history ( N = 507,889; 1.04 [1.02, 1.06]), and Age65 + ( N = 592,123, 1.59 [1.52, 1.66]). Incident COPD was associated with subsequent MACE in CKD only (1.28 [1.13, 1.45]). Being at risk of COPD was associated with subsequent MACE in CKD (1.18 [1.07, 1.30]), MACE history (1.16 [1.08, 1.25]), and Age65 + (1.28 [1.13, 1.46]). ICS prescription was not associated with subsequent MACE in any concurrent CKM-COPD cohort. Conclusions: COPD was an independent risk factor for MACE in CKM populations. ICS did not attenuate MACE amongst CKM-COPD groups. Incident COPD was associated with MACE in CKD, and being at risk of COPD was associated with MACE in CKD, MACE history, and Age65 + cohorts.
- 4 March 2026
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Open AccessThe role of COPD and inhaled corticosteroids in major adverse cardiovascular events in cardiovascular-kidney-metabolic populations
Background: Cardiovascular-kidney-metabolic (CKM) disease and chronic obstructive pulmonary disease (COPD) are associated with major adverse cardiovascular events (MACE). Whether COPD further increases MACE risk within CKM populations, and whether this potential risk is modifiable through inhaled corticosteroids (ICS), is unknown. Within CKM populations, we investigated the relationship between (1) COPD and subsequent MACE, and (2) amongst concurrent CKM-COPD populations, we investigated the relationship between ICS and subsequent MACE. Methods: We used Clinical Practice Research Datalink (CPRD) Aurum, Hospital Episode Statistics and Office of National Statistics data, between January 1st, 2010, and March 29th, 2021. We created five discrete cohorts: chronic kidney disease (CKD), type-II diabetes mellitus (T2DM), obesity, MACE history, and older adults (aged ≥ 65 years old [“Age65 + ”]). CKD, T2DM, obesity, and Age65 + cohorts were MACE-naïve at the time of inclusion. Aim (1) exposures were (a) COPD, (b) incident COPD, and (c) being at risk of COPD without diagnosis (defined as age ≥ 40 years old, smoking history, no evidence of asthma, and frequent respiratory infections requiring antibiotics). Aim (2) exposure was ICS prescription (control group: long-acting bronchodilators). The outcome was MACE (acute coronary syndrome, arrhythmia, heart failure, ischaemic stroke, or cardiovascular-specific mortality). We implemented Cox proportional hazards models. Results: COPD was associated with MACE amongst all cohorts, but was comparatively weak in the MACE history cohort (cohort total; adjusted hazard ratio [95% confidence interval]): CKD ( N = 573,626; 1.29 [1.26, 1.32]), T2DM ( N = 649,506; 1.30 [1.26, 1.35], obesity ( N = 225,273; 1.41 [1.34, 1.48]), MACE history ( N = 507,889; 1.04 [1.02, 1.06]), and Age65 + ( N = 592,123, 1.59 [1.52, 1.66]). Incident COPD was associated with subsequent MACE in CKD only (1.28 [1.13, 1.45]). Being at risk of COPD was associated with subsequent MACE in CKD (1.18 [1.07, 1.30]), MACE history (1.16 [1.08, 1.25]), and Age65 + (1.28 [1.13, 1.46]). ICS prescription was not associated with subsequent MACE in any concurrent CKM-COPD cohort. Conclusions: COPD was an independent risk factor for MACE in CKM populations. ICS did not attenuate MACE amongst CKM-COPD groups. Incident COPD was associated with MACE in CKD, and being at risk of COPD was associated with MACE in CKD, MACE history, and Age65 + cohorts.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 2549-2560
Major Adverse Cardiovascular Events and Cause-Specific Mortality After Hospitalisation in COPD
Purpose: People with chronic obstructive pulmonary disease (COPD) are at elevated risk of cardiovascular events and mortality. We aimed to determine, in a COPD population, the relationship between hospitalization and post-discharge one-year rates of (i) major adverse cardiovascular events (MACE) and (ii) cause-specific mortality. Patients and Methods: We conducted a prospective cohort study on a COPD population, between 01/01/2010 and 31/12/2019, using nationally-representative, routinely collected electronic healthcare records in England (Clinical Practice Research Datalink Aurum primary care data, linked with secondary care [Hospital Episode Statistics], and mortality [Office of National Statistics] data). The exposure was ≥one hospitalization, and the control group was no hospitalization. Outcomes were one-year rates of (i) non-fatal MACE (acute coronary syndrome, arrhythmia, heart failure, or ischemic stroke) and (ii) cause-specific mortality. Exposures were stratified by hospitalization type (elective and emergency) and cause (all-cause, cardiovascular, respiratory, and non-cardiorespiratory). We implemented adjusted Cox proportional hazard regression models, and sensitivity doubly robust propensity score-adjusted models. Results: Hospitalized COPD patients had significantly higher rates (incidence rate [IR, per 1000 person-years]; adjusted hazard ratio {aHR} [95% confidence interval {95% CI}] of MACE in the year following hospitalization, whether elective (IR=33.3; 7.04 [6.19– 8.07]) or emergency (IR=70.0; 8.85 [7.78– 10.06]), versus those without hospitalization (IR=3.4). Emergency hospitalization was associated with increased all-cause mortality (IR=146.5; 2.49 [2.37– 2.61]), regardless of hospitalization cause, compared to those not hospitalized (IR=30.3). Elective hospitalization was also associated with increased all-cause mortality (IR=54.6; 1.32 [1.25– 1.38]), except for cardiovascular elective hospitalization (1.00 [0.89– 1.12]). Cause-specific mortality was influenced largely by hospitalization cause. Conclusion: Hospitalized COPD patients experienced increased subsequent one-year MACE and mortality rates, regardless of hospitalization cause or type. Hospitalization for any reason in COPD patients provides an opportunity to provide primary prevention for MACE.
- 1 July 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 2549-2560
Open AccessMajor Adverse Cardiovascular Events and Cause-Specific Mortality After Hospitalisation in COPD
Purpose: People with chronic obstructive pulmonary disease (COPD) are at elevated risk of cardiovascular events and mortality. We aimed to determine, in a COPD population, the relationship between hospitalization and post-discharge one-year rates of (i) major adverse cardiovascular events (MACE) and (ii) cause-specific mortality. Patients and Methods: We conducted a prospective cohort study on a COPD population, between 01/01/2010 and 31/12/2019, using nationally-representative, routinely collected electronic healthcare records in England (Clinical Practice Research Datalink Aurum primary care data, linked with secondary care [Hospital Episode Statistics], and mortality [Office of National Statistics] data). The exposure was ≥one hospitalization, and the control group was no hospitalization. Outcomes were one-year rates of (i) non-fatal MACE (acute coronary syndrome, arrhythmia, heart failure, or ischemic stroke) and (ii) cause-specific mortality. Exposures were stratified by hospitalization type (elective and emergency) and cause (all-cause, cardiovascular, respiratory, and non-cardiorespiratory). We implemented adjusted Cox proportional hazard regression models, and sensitivity doubly robust propensity score-adjusted models. Results: Hospitalized COPD patients had significantly higher rates (incidence rate [IR, per 1000 person-years]; adjusted hazard ratio {aHR} [95% confidence interval {95% CI}] of MACE in the year following hospitalization, whether elective (IR=33.3; 7.04 [6.19– 8.07]) or emergency (IR=70.0; 8.85 [7.78– 10.06]), versus those without hospitalization (IR=3.4). Emergency hospitalization was associated with increased all-cause mortality (IR=146.5; 2.49 [2.37– 2.61]), regardless of hospitalization cause, compared to those not hospitalized (IR=30.3). Elective hospitalization was also associated with increased all-cause mortality (IR=54.6; 1.32 [1.25– 1.38]), except for cardiovascular elective hospitalization (1.00 [0.89– 1.12]). Cause-specific mortality was influenced largely by hospitalization cause. Conclusion: Hospitalized COPD patients experienced increased subsequent one-year MACE and mortality rates, regardless of hospitalization cause or type. Hospitalization for any reason in COPD patients provides an opportunity to provide primary prevention for MACE.
- Open Access
Inhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease
Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated. Objectives To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared with long-acting bronchodilators; and (2) whether drug class, incident usership or patient cardiovascular history influenced the ICS-MACE relationship. Methods We conducted a cohort study including patients with COPD in England, using Clinical Practice Research Datalink Aurum data, linked with Hospital Episode Statistics and Office of National Statistics death data, between 1 January 2010 and 31 December 2019. We implemented Cox proportional hazard regressions, adjusting for time interactions or using propensity score-adjusted models, as necessary. Our exposures included prescriptions of any ICS (vs any long-acting bronchodilators) and triple therapy (vs combination long-acting bronchodilators), determined during the year prior to follow-up. The outcomes of interest were MACE collectively and individual MACE subtypes. Measurements and main results Among 113 353 people with COPD (mean age 67.9 years old, 53.3% male), ICS prescription was not associated with MACE (adjusted HR (95% CI)=0.98 (0.95, 1.02), p=0.41) but was associated with reduced HF, specifically, until year 6 of follow-up (average adjusted HR (95% CI)=0.91 (0.86, 0.96), pConclusions ICS did not reduce MACE, except HF, likely by reducing misclassified COPD exacerbations.
Open AccessInhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease
Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated. Objectives To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared with long-acting bronchodilators; and (2) whether drug class, incident usership or patient cardiovascular history influenced the ICS-MACE relationship. Methods We conducted a cohort study including patients with COPD in England, using Clinical Practice Research Datalink Aurum data, linked with Hospital Episode Statistics and Office of National Statistics death data, between 1 January 2010 and 31 December 2019. We implemented Cox proportional hazard regressions, adjusting for time interactions or using propensity score-adjusted models, as necessary. Our exposures included prescriptions of any ICS (vs any long-acting bronchodilators) and triple therapy (vs combination long-acting bronchodilators), determined during the year prior to follow-up. The outcomes of interest were MACE collectively and individual MACE subtypes. Measurements and main results Among 113 353 people with COPD (mean age 67.9 years old, 53.3% male), ICS prescription was not associated with MACE (adjusted HR (95% CI)=0.98 (0.95, 1.02), p=0.41) but was associated with reduced HF, specifically, until year 6 of follow-up (average adjusted HR (95% CI)=0.91 (0.86, 0.96), pConclusions ICS did not reduce MACE, except HF, likely by reducing misclassified COPD exacerbations.
- Open Access
- 28 August 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e002273
Patient pathways for four major chronic respiratory diseases in England between 2008 and 2021
Background Not all chronic diseases have clear pathways and time targets for diagnosis. We explored pathways and timings for four major chronic respiratory diseases in England. Methods Using deidentified electronic healthcare records from Clinical Practice Research Datalink Aurum linked to Hospital Episode Statistics, we derived cohorts of patients diagnosed with asthma, chronic obstructive pulmonary disease (COPD), ILD or bronchiectasis at three time periods (2008/2009, 2018/2019 and 2020/2021). We followed people 2 years before and 2 years after diagnosis, calculating the proportion of people who presented with symptoms, underwent diagnostic tests, were treated and consulted healthcare (primary or secondary) and calculated time intervals between events. We repeated analyses by socioeconomic status and geographical region. Results We descriptively studied patient pathways for 429 619 individuals across all time frames and diseases. Most people (>87%) had first evidence of diagnosis in primary care. The proportion of people reporting symptoms prior to diagnosis was similar for asthma, COPD and ILD (41.0%–57.9%) and higher in bronchiectasis (67.9%–71.8%). The proportion undergoing diagnostic tests was high for COPD and bronchiectasis (77.6%–89.2%) and lower for asthma (14%–32.7%) and ILD (2.6%–3.3%). The proportion of people undergoing diagnostic tests decreased in 2020/2021 for all diseases, mostly COPD. Time (months) (median (IQR)) between symptoms and diagnosis, averaged over three time periods, was lowest in asthma (~7.5 (1.3–16.0)), followed by COPD (~8.6 (1.8–17.2)), ILD (~10.1 (3.6–18.0)) and bronchiectasis (~13.5 (5.9–19.8)). Time from symptoms to diagnosis increased by ~2 months in asthma and COPD over the three time periods. Although most patients were symptomatically treated prior to diagnosis, time between diagnosis and postdiagnostic treatment was around 4 months for ILD, 3 months for bronchiectasis and instantaneous for asthma and COPD. Socioeconomic status and regional trends showed little disparity. Conclusion Current pathways demonstrate missed opportunities to diagnose and manage disease and to improve disease coding.
- 28 August 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e002273
Open AccessPatient pathways for four major chronic respiratory diseases in England between 2008 and 2021
Background Not all chronic diseases have clear pathways and time targets for diagnosis. We explored pathways and timings for four major chronic respiratory diseases in England. Methods Using deidentified electronic healthcare records from Clinical Practice Research Datalink Aurum linked to Hospital Episode Statistics, we derived cohorts of patients diagnosed with asthma, chronic obstructive pulmonary disease (COPD), ILD or bronchiectasis at three time periods (2008/2009, 2018/2019 and 2020/2021). We followed people 2 years before and 2 years after diagnosis, calculating the proportion of people who presented with symptoms, underwent diagnostic tests, were treated and consulted healthcare (primary or secondary) and calculated time intervals between events. We repeated analyses by socioeconomic status and geographical region. Results We descriptively studied patient pathways for 429 619 individuals across all time frames and diseases. Most people (>87%) had first evidence of diagnosis in primary care. The proportion of people reporting symptoms prior to diagnosis was similar for asthma, COPD and ILD (41.0%–57.9%) and higher in bronchiectasis (67.9%–71.8%). The proportion undergoing diagnostic tests was high for COPD and bronchiectasis (77.6%–89.2%) and lower for asthma (14%–32.7%) and ILD (2.6%–3.3%). The proportion of people undergoing diagnostic tests decreased in 2020/2021 for all diseases, mostly COPD. Time (months) (median (IQR)) between symptoms and diagnosis, averaged over three time periods, was lowest in asthma (~7.5 (1.3–16.0)), followed by COPD (~8.6 (1.8–17.2)), ILD (~10.1 (3.6–18.0)) and bronchiectasis (~13.5 (5.9–19.8)). Time from symptoms to diagnosis increased by ~2 months in asthma and COPD over the three time periods. Although most patients were symptomatically treated prior to diagnosis, time between diagnosis and postdiagnostic treatment was around 4 months for ILD, 3 months for bronchiectasis and instantaneous for asthma and COPD. Socioeconomic status and regional trends showed little disparity. Conclusion Current pathways demonstrate missed opportunities to diagnose and manage disease and to improve disease coding.
- Top Cited PapersOpen Access
- 15 April 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (8) , 960-972
Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study
Rationale: Cardiovascular events after chronic obstructive pulmonary disease (COPD) exacerbations are recognized. Studies to date have been post hoc analyses of trials, did not differentiate exacerbation severity, included death in the cardiovascular outcome, or had insufficient power to explore individual outcomes temporally. Objectives: We explore temporal relationships between moderate and severe exacerbations and incident, nonfatal hospitalized cardiovascular events in a primary care–derived COPD cohort. Methods: We included people with COPD in England from 2014 to 2020, from the Clinical Practice Research Datalink Aurum primary care database. The index date was the date of first COPD exacerbation or, for those without exacerbations, date upon eligibility. We determined composite and individual cardiovascular events (acute coronary syndrome, arrhythmia, heart failure, ischemic stroke, and pulmonary hypertension) from linked hospital data. Adjusted Cox regression models were used to estimate average and time-stratified adjusted hazard ratios (aHRs). Measurements and Main Results: Among 213,466 patients, 146,448 (68.6%) had any exacerbation; 119,124 (55.8%) had moderate exacerbations, and 27,324 (12.8%) had severe exacerbations. A total of 40,773 cardiovascular events were recorded. There was an immediate period of cardiovascular relative rate after any exacerbation (1–14 d; aHR, 3.19 [95% confidence interval (CI), 2.71–3.76]), followed by progressively declining yet maintained effects, elevated after one year (aHR, 1.84 [95% CI, 1.78–1.91]). Hazard ratios were highest 1–14 days after severe exacerbations (aHR, 14.5 [95% CI, 12.2–17.3]) but highest 14–30 days after moderate exacerbations (aHR, 1.94 [95% CI, 1.63–2.31]). Cardiovascular outcomes with the greatest two-week effects after a severe exacerbation were arrhythmia (aHR, 12.7 [95% CI, 10.3–15.7]) and heart failure (aHR, 8.31 [95% CI, 6.79–10.2]). Conclusions: Cardiovascular events after moderate COPD exacerbations occur slightly later than after severe exacerbations; heightened relative rates remain beyond one year irrespective of severity. The period immediately after an exacerbation presents a critical opportunity for clinical intervention and treatment optimization to prevent future cardiovascular events.
- 15 April 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (8) , 960-972
Top Cited PapersOpen AccessTemporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study
Rationale: Cardiovascular events after chronic obstructive pulmonary disease (COPD) exacerbations are recognized. Studies to date have been post hoc analyses of trials, did not differentiate exacerbation severity, included death in the cardiovascular outcome, or had insufficient power to explore individual outcomes temporally. Objectives: We explore temporal relationships between moderate and severe exacerbations and incident, nonfatal hospitalized cardiovascular events in a primary care–derived COPD cohort. Methods: We included people with COPD in England from 2014 to 2020, from the Clinical Practice Research Datalink Aurum primary care database. The index date was the date of first COPD exacerbation or, for those without exacerbations, date upon eligibility. We determined composite and individual cardiovascular events (acute coronary syndrome, arrhythmia, heart failure, ischemic stroke, and pulmonary hypertension) from linked hospital data. Adjusted Cox regression models were used to estimate average and time-stratified adjusted hazard ratios (aHRs). Measurements and Main Results: Among 213,466 patients, 146,448 (68.6%) had any exacerbation; 119,124 (55.8%) had moderate exacerbations, and 27,324 (12.8%) had severe exacerbations. A total of 40,773 cardiovascular events were recorded. There was an immediate period of cardiovascular relative rate after any exacerbation (1–14 d; aHR, 3.19 [95% confidence interval (CI), 2.71–3.76]), followed by progressively declining yet maintained effects, elevated after one year (aHR, 1.84 [95% CI, 1.78–1.91]). Hazard ratios were highest 1–14 days after severe exacerbations (aHR, 14.5 [95% CI, 12.2–17.3]) but highest 14–30 days after moderate exacerbations (aHR, 1.94 [95% CI, 1.63–2.31]). Cardiovascular outcomes with the greatest two-week effects after a severe exacerbation were arrhythmia (aHR, 12.7 [95% CI, 10.3–15.7]) and heart failure (aHR, 8.31 [95% CI, 6.79–10.2]). Conclusions: Cardiovascular events after moderate COPD exacerbations occur slightly later than after severe exacerbations; heightened relative rates remain beyond one year irrespective of severity. The period immediately after an exacerbation presents a critical opportunity for clinical intervention and treatment optimization to prevent future cardiovascular events.
- Open Access
- 3 October 2023
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 17 (10) , 937-950
Spirometry in atrial fibrillation: what’s the catch?
People with COPD rarely have COPD alone, and the commonest co-morbidities occurring with COPD are cardiovascular. Whilst multiple studies have explored the association between major cardiovascular events and COPD, less attention has been paid to arrhythmias, specifically atrial fibrillation (AF). AF and COPD frequently occur together, posing challenges in diagnosis and management. In this review, we describe the relationship between AF and COPD epidemiologically and physiologically, demonstrating the role of spirometry as a diagnostic and disease management tool. We provide epidemiological evidence that COPD and AF are independent risk factors for one another, that either disease is highly prevalent amongst people with the other, and that they have shared risk factors; all of which contribute to adverse prognostic. We elucidated common pathophysiological mechanisms implicated in AF-COPD. We ultimately present the epidemiological and physiological evidence with a view to highlight specific areas where we feel spirometry is of value in the management of AF-COPD. AF and COPD commonly co-occur, there is often diagnostic delay, increased risk of reduced cardioversion success, and missed opportunity to intervene to reduce stroke risk. Greater awareness and timelier diagnosis and guideline directed management may improve outcomes for people with both diseases.
- 3 October 2023
- Published by Taylor & Francis in Expert Review of Respiratory Medicine
- Vol. 17 (10) , 937-950
Open AccessSpirometry in atrial fibrillation: what’s the catch?
People with COPD rarely have COPD alone, and the commonest co-morbidities occurring with COPD are cardiovascular. Whilst multiple studies have explored the association between major cardiovascular events and COPD, less attention has been paid to arrhythmias, specifically atrial fibrillation (AF). AF and COPD frequently occur together, posing challenges in diagnosis and management. In this review, we describe the relationship between AF and COPD epidemiologically and physiologically, demonstrating the role of spirometry as a diagnostic and disease management tool. We provide epidemiological evidence that COPD and AF are independent risk factors for one another, that either disease is highly prevalent amongst people with the other, and that they have shared risk factors; all of which contribute to adverse prognostic. We elucidated common pathophysiological mechanisms implicated in AF-COPD. We ultimately present the epidemiological and physiological evidence with a view to highlight specific areas where we feel spirometry is of value in the management of AF-COPD. AF and COPD commonly co-occur, there is often diagnostic delay, increased risk of reduced cardioversion success, and missed opportunity to intervene to reduce stroke risk. Greater awareness and timelier diagnosis and guideline directed management may improve outcomes for people with both diseases.